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Abstract
The search for new macrofilaricidal drugs against onchocerciasis that can be administered
in shorter regimens than required for doxycycline (DOX, 200mg/d given for 4–6 weeks),
identified minocycline (MIN) with superior efficacy to DOX. Further reduction in the treat-
ment regimen may be achieved with co-administration with standard anti-filarial drugs.
Therefore a randomized, open-label, pilot trial was carried out in an area in Ghana endemic
for onchocerciasis, comprising 5 different regimens: the standard regimen DOX 200mg/d
for 4 weeks (DOX 4w, N = 33), the experimental regimens MIN 200mg/d for 3 weeks (MIN
3w; N = 30), DOX 200mg/d for 3 weeks plus albendazole (ALB) 800mg/d for 3 days (DOX
3w + ALB 3d, N = 32), DOX 200mg/d for 3 weeks (DOX 3w, N = 31) and ALB 800mg for 3
days (ALB 3d, N = 30). Out of 158 randomized participants, 116 (74.4%) were present for
the follow-up at 6 months of whom 99 participants (63.5%) followed the treatment per proto-
col and underwent surgery. Histological analysis of the adult worms in the extirpated nod-
ules revealed absence of Wolbachia in 98.8% (DOX 4w), 81.4% (DOX 3w + ALB 3d), 72.7%
(MIN 3w), 64.1% (DOX 3w) and 35.2% (ALB 3d) of the female worms. All 4 treatment regi-
mens showed superiority to ALB 3d (p < 0.001, p < 0.001, p = 0.002, p = 0.008, respec-
tively), which was confirmed by real-time PCR. Additionally, DOX 4w showed superiority to
all other treatment arms. Furthermore DOX 4w and DOX 3w + ALB 3d showed a higher
amount of female worms with degenerated embryogenesis compared to ALB 3d (p = 0.028,
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p = 0.042, respectively). These results confirm earlier studies that DOX 4w is sufficient for
Wolbachia depletion and the desired parasitological effects. The data further suggest that
there is an additive effect of ALB (3 days) on top of that of DOX alone, and that MIN shows a
trend for stronger potency than DOX. These latter two results are preliminary and need con-
firmation in a fully randomized controlled phase 2 trial.
Trial Registration: ClinicalTrials.gov #06010453
Author Summary
Onchocerciasis is a vector borne disease that is still a major health burden in endemic
countries, despite twenty years of control that has led to effective control and reduction of
blindness and morbidity in West Africa. To reach the goal of onchocerciasis elimination,
alternative strategies are needed to overcome existing hurdles. Ivermectin is used for mass
drug administration (MDA) and kills the microfilariae, thus preventing uptake by the vec-
tor and reducing transmission. Since adult worms live for 10 years or longer, MDA
requires many years of treatment, a heavy burden on health care systems. Inadequate pop-
ulation coverage, sub-optimal responses, possible development of resistance and the risk
of severe adverse reactions with co-endemic Loiasis are current hurdles for achieving
elimination. The search for new drugs that could enhance elimination by permanently
sterilizing and killing the adult worms has identified a 4–6 weeks course of doxycycline, a
slow-killing drug due to its indirect mode of action by killing endosymbiotic bacteria. The
present study aimed to investigate a new anti-Wolbachia drug, minocycline, and doxycy-
cline in combination with one of the standard broad-spectrum anti-helminthic drugs,
albendazole, to identify shorter treatment regimens. Our data confirm the efficacy of a 4-
weeks doxycycline regimen and show that albendazole has additive effects when used in
combination with doxycycline. In addition, comparison of a 3-week course of minocy-
cline with a 3-week course of doxycycline revealed a trend for stronger efficacy of minocy-
cline. Further development of anti-Wolbachia and anti-filarial drug combinations are
warranted to improve treatment options to overcome existing hurdles and for use in
“end-game” scenarios when switching from MDA to “test & treat” strategies.
Introduction
More than 200 million humans are parasitized by filarial nematodes, causing the neglected
tropical diseases: lymphatic filariasis, loiasis and onchocerciasis. The lymphatic, ocular and
dermatological pathologies have severe economic and social consequences including poor
school performance, low productivity, higher health related costs among infected adults and a
reduced life span [1–3]. In onchocerciasis, several programs and developments have greatly
improved the situation in Africa since the 1970’s when the Onchocerciasis Control Pro-
gramme (OCP), a programme relying on vector control, in West Africa was initiated. In 1987,
a new treatment-based strategy was made possible due to the donation of ivermectin (IVM) by
Merck as long as needed and the African Programme for Onchocerciasis Control (APOC), a
coordinated community directed distribution of IVM mass drug administration (MDA) in 28
African countries [4] that has now ended in 2015, was launched. Despite the tremendous prog-
ress [5], disease elimination will require continuity and new approaches with APOC and
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onchocerciasis control are being integrated into the Expanded Special Project for Elimination
of Neglected Tropical Diseases (ESPEN).
A major problem with the current treatment is that IVM has minimal efficacy against adult
worms and does not permanently stop microfilariae (Mf) production. Simulation studies have
suggested that administering IVM at shorter intervals of 6 instead of 12 months intervals have
a higher likelihood of eliminating the infection, but incur large logistical costs on health infra-
structures of the endemic countries [6, 7]. Immigration of infected persons into areas where
filariasis is considered eliminated and IVM treatment has ceased may occur with potential re-
emergence of the disease. Equally important is the evidence of persistent IVM suboptimal effi-
cacy in some communities [8–11], which is of particular concern as there is currently no alter-
native treatment suitable for MDA.
In addition, MDA cannot easily be undertaken in regions endemic for onchocerciasis,
where patients are co-infected with Loa loa (primarily in Central Africa) and which are esti-
mated to cover at least 20% of onchocerciasis-endemic areas [12]. This is because microfilarici-
dal drugs also kill Loa loa Mf and in patients with high parasitemia this may elicit loiasis-
specific adverse reactions (Loa loa encephalopathy), leading to severe neurological disorders
or death [13]. Thus there is an urgent need for a safe macrofilaricide, targeting adult worms
that can be used for onchocerciasis and LF, particularly in problem areas, such as those with
emerging ivermectin resistance or Loa loa co-endemicity. Further development of anti-Wolba-
chia macrofilaricides is therefore warranted to improve treatment options to overcome exist-
ing hurdles and for use in “end-game” scenarios in areas with hypoendemicity or when
switching from MDA to “test & treat” strategies (who.int/apoc/ATS_Report_2015.12).
Targeting Wolbachia endosymbionts by antibiotics is an alternative approach that has been
verified by a number of clinical trials in onchocerciasis [14–16] and LF [17–21]. Depletion of
Wolbachia leads to long-term sterilization and to a macrofilaricidal effect. This has been
shown first in animal models [22–24] and was successfully translated into clinical trials in
human onchocerciasis [15] and lymphatic filariasis [21, 25]. A recent meta-analysis on the
available data from clinical trials in onchocerciasis has shown that the 3 so far used regimens,
doxycycline (DOX) 200 mg/day for 4 weeks, DOX 200 mg/day for 6 weeks [15], and DOX 100
mg/day for 5 weeks [26] are broadly equivalent, in particular with regards to the sterilizing
effects of adult female worms [27], and therefore DOX treatment with 200 mg/day for 4 weeks
can be considered as a “standard” anti-wolbachial therapy for onchocerciasis.
The advantages of DOX for the depletion of Wolbachia endobacteria have stimulated the
development of new drugs. The indirect mode of action with its slow antifilarial activity
confers an excellent safety profile by avoiding inflammatory reactions [28] and can safely be
used in L. loa coendemic areas, since this filarial parasite does not contain Wolbachia. The
AWOL Consortium was established to find new anti-wolbachial drugs or drug combina-
tions that are deliverable in a shorter regimen, with a secondary goal to optimize regimens
using currently known anti-Wolbachia antibiotics (www.a-wol.com). The tetracycline deri-
vate minocycline (MIN), was identified as priority hit in the cell culture screening assay
[29] as well as on adult O. gutturosa male worms [3] and in the L. sigmodontis animal model
[30]. Albendazole (ALB) is widely used in combination with IVM for lymphatic filariasis
and soil transmitted helminths, yet no clear evidence for efficacy against onchocerciasis has
been provided.
Here, we present the results of a randomized open pilot-trial to compare DOX, MIN, as
well as the combination of DOX plus ALB to ALB alone in their efficacy against onchocercia-
sis. The underlying rationale that led to the design of this trial was to provide a shortened treat-
ment that is equally efficient in Wolbachia depletion or blockage of embryogenesis after 6
months as the current regimen of 4 weeks DOX 200mg compared to 3 days ALB 800 mg.
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Materials and Methods
Study population and ethics statement
This study was undertaken in 14 villages adjacent to the river Offin in Ghana (Upper and
Lower Denkyira Districts in the Central Region and the Amansie Central and Adanse South
Districts in the Ashanti Region). These rain forest areas are within the distribution range of
the vector (<12 km from the breeding site, the river Offin and affluent creeks) and hyperen-
demic for onchocerciasis but not for other filarial infections and were not part of either OCP
or APOC programs. MDA has been implemented by the Ghanaian Ministry of Health since
2001 in Upper and Lower Denkyira districts and from 2008 in the Amansie and Adanse South
areas. However, MDA compliance has not met MDA targets in all areas, especially in the
Upper and Lower Denkyira districts, and therefore, at the time of sampling a considerable
number of people had not or not frequently taken part in IVM therapy. This study was
approved by the Committee on Human Research, Publications and Ethics of the School of
Medical Sciences of the Kwame Nkrumah University of Science and Technology (KNUST),
Kumasi, Ghana,—Research Ethics Committee of the Liverpool School of Tropical Medicine as
well as the Ethical Committee of the University Hospital of Bonn, Germany. The trial was reg-
istered at Current Controlled Trials (www.isrctn.com, # 06010453).
Eligible for this study were healthy male and female patients (without clinical conditions
requiring long-term medication and normal renal and hepatic laboratory profiles), aged
between 18–55 years, > 40 kg of body weight and the presence of at least one palpable oncho-
cercoma. Hepatic and renal functions as well as pregnancy tests were assessed by dipstick
chemistry using venous blood and urine. Skin snips (biopsies) were taken to determine skin
microfilarial (Mf) loads. Exclusion criteria were: abnormal hepatic and renal enzymes, preg-
nancy, breast-feeding, intolerance to the study drugs, alcohol or drug abuse, history of TB, glu-
cose in urine, hypertension or history of any condition requiring long term medication (see
also ISRCTN registry). Written informed consent was obtained from all individuals. A Data
Monitoring and Ethic Committee (DMEC) was established prior to this study.
Study design, randomization and interventions
This study is a randomized, open, clinical phase 2a drug trial. The purpose of the 5 different treat-
ment regimens was to determine if a reduced treatment period could be achieved using doxycy-
cline 200mg alone for 3 weeks (DOX 3w), doxycycline 200mg for 3 weeks plus 3 days albendazole
(DOX 3w+ALB 3d), minocycline 200mg for 3 weeks (MIN 3w) or doxycycline 200mg for 4 weeks
(DOX 4w) as standard anti-wolbachial regimen compared to albendazole 800mg for 3 days (ALB
3d), which is considered equivalent to an untreated control arm, when given on its own [31].
This study was a pilot trial to gain first experience regarding the primary and secondary
endpoints under the intended treatment regimens. Therefore a sample size of 30 participants
(20 participants plus 50% drop-out rate) per treatment arm was chosen in line with the sample
sizes normally taken for pilot trials. Participants were randomly assigned to one of 5 treatment
arms according to their participation in the MDA and their Mf-status as follows:
1. Mf-positive (> 10 Mf/mg skin) or > 2 palpable onchocercomata: no limitation of ivermec-
tin (MDA) rounds;
2. Mf-positive (0.1–10 Mf/mg skin) and 2 palpable onchocercomata: last ivermectin
treatment > 1 year ago and not more than 3 rounds;
3. Mf-negative (0 Mf/mg skin) 2 palpable onchocercomata: last ivermectin treatment > 1
year ago and not more than 1 round.
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Participants received the study drugs under daily observation. Participants were given IVM
after the nodulectomies. After study completion, DOX 4w was offered to all participants. Even
though the study was an open trial and therefore participants as well as the trial clinicians were
not blinded for the treatment, the outcome assessors (histology and PCR) were blinded for the
treatment allocation.
Primary outcome of this trial was the absence of Wolbachia endobacteria in adult living
female worms assessed by immunohistology 6 months after treatment. Secondary outcomes
were the quantitative evaluation of Wolbachia endobacteria reduction after 6 months by immu-
nohistology as well as by PCR. Furthermore reduction and presence or absence of Mf in the skin
and embryogenesis within the worms as well as the number of live or dead worms was evaluated.
Parasitological assessment
All infected patients presented at least one palpable nodule [32]. For Mf analysis, two skin
biopsies of 1–3 mg were taken from the buttocks using a corneoscleral (Holth) punch. Each
biopsy was immersed in 100 ml of 0.9% NaCl solution in a well of a microtiter plate. The skin
biopsies were incubated overnight at room temperature to allow Mf to emerge. The solution
was then transferred onto a slide for microscopic examination [15, 33]. The biopsies were
weighed using an electronical balance and Mf load was calculated per mg skin. The presence
of further parasitic infections were assessed using standard diagnostic tests on stool and urine
samples [34]. Five participants were positive for hookworm, one for Giardia lamblia and one
for Strongyloides.
Histological assessment
Nodules were fixed in 80% ethanol or 4% phosphate buffered formaldehyde solution. Samples
were embedded in paraffin and several sections were stained with hematoxylin and eosin,
Gomori’s method for iron, or immunostained using antibodies against Dirofilaria immitis
Wolbachia surface protein (Diwsp) or Wolbachia PAL-lipoprotein (wBmPAL) for presence of
Wolbachia and cathepsin D-like lysosomal aspartic protease of O. volvulus (APR) for worm
vitality [35]. Thereby at least 8 sections across the nodules were histologically assessed as
described previously [36, 37]. In brief, characteristics for death of a worm included loss of
body wall integrity, loss of nuclei of all organs and absence of APR-staining. Very degenerated
worms, still APR-positive, were classified as moribund and grouped in the category “dead”.
The designation “living” refers to worms judged as being alive at the time of nodulectomy.
Characteristics for differentiation include the size, general organ or tissue structure as well as
iron deposition in the intestine of the worm. The age of the living worms was estimated as
"newly acquired", “young”, “middle”, “old” (see Fig 2) [37]. Thirteen male worms were defined
as newly acquired. They were not subtracted from this analysis because these worms could
have been acquired already shortly before treatment onset. The classification of Wolbachia
content was: no Wolbachia (negative for Diwsp or wBmPAL staining), few or many. Since
Wolbachia are densely packed within the hypodermis, the female worms containing such con-
glomerates were assigned as many, whereas those female worms containing visible Wolbachia
(<50) but not in dense packages were assigned as few (see Fig 2). Developmental stages from
the two-cell stage through to stretched Mf in the uterus were classified as “embryos”. When
only the stretched Mf were degenerated and the other embryo stages were not, embryogenesis
was recorded as “normal” for the purpose of this tetracycline-oriented study, since the previ-
ous IVM treatment would have conferred precisely these effects, i.e. degeneration of intra-
uterine Mf (in addition to killing of skin Mf). The sections were assessed by two experienced
parasitologists (SS, BD).
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PCR
For DNA extraction 8 nodule paraffin sections of 4 μm were placed in microcentrifuge tubes
and DNA was extracted according to the manufacturer’s instructions (Quiamp DNA Mini Kit).
The Wolbachia ftsZ and O. volvulus actin gene were quantified from the purified DNA by real-
time duplex PCR (qPCR) using the following conditions: 10x HotStar Taq Polymerase buffer
(Qiagen), 200 μM dNTP, Primers: OvFtsZ forward primer (aggaatgggtggtggtactg), OvFtsZ
reverse primer (ctttaaccgcagctcttgct), OvActin forward primer (gtgctacgttgctttggact), OvActin
reverse primer (gtaatcacttggccatcagg), OvFtsZ taqman probe (5’6-FAM ccttgccgctttcgcaatcac
3’DDQ-1), OvActin taqman probe(5’HEX aacaggaaatggcaactgctgc 3’BHQ-1), 2.5 units HotStar
Taq, and 2 μl DNA in a 20 μl reaction. Final primer concentrations were 400 nM for OvwFtsZ
and OvActin, final taqman probe concentrations were 25 nM for OvwFtsZ and 50 nM for
OvActin and 6 mM for the MgCl2 concentration. Genes were amplified in a Rotorgene 3000
(Quiagen, Hilden, Germany) using the following conditions: 1X 15 min at 95˚C, 45 cycles of
95˚C for 15 sec, 58˚C for 30 sec. Fluorescence was acquired on the FAM and JOE channel.
Statistics
Analyses were done using SPSS (IBM SPSS Statistics 22; Armonk, NY) and SAS version 9.2
(SAS Institute Inc. Cary, NC, USA).
Three data sets (per protocol, PP; intention to treat, ITT; Mf-PP) were used to analyze the
data (Fig 1). The intention to treat set (ITT) includes all patients who were randomized to one
Fig 1. Flow chart of volunteers who took part in the study.
doi:10.1371/journal.pntd.0005156.g001
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of the 5 treatment regimens and who took the drugs at least once. The PP set is a subset of the
ITT set and includes all patients who completed the treatment without any violations of the
protocol and were present for nodulectomies 6 months after treatment onset. Since this is a
non-confirmatory pilot-trial all endpoint analyses were primarily carried out using the PP set.
The ITT set was used to describe the baseline data, the adverse events and for confirmation of
the PP analyses. For the ITT outcome analyses of the histological and PCR results we included
all operated individuals, missing values were not replaced. Additionally, we set up a data set,
including all patients present for skin-snipping before treatment onset as well as at the 6
months follow-up (Mf-PP).
Alternating regression, as implemented in the SAS-Procedure Genmod, was used to analyze
the histological and PCR data. This procedure allows accounting for a potential dependency
Fig 2. Histological analysis of endobacteria content and worm age. Worms were categorized using three different staining methods, i.e.
APR (a, d, g), anti-Diwsp or wBmPAL (b, e, h) and iron staining (c, f, i). Worms were alive at the time of nodulectomy (a, d, g), when they stained
positive for APR in the hypodermis, embryos, gut and uteri, whereas dead worms were APR-negative (a, *). Wolbachia levels were categorized
as negative (b, <), few (e, <) or many (h, <). In addition, age of the worms was estimated as described previously and included a combination of
size, general organ and tissue structure (a, b, d, e, g, h) as well as iron deposition in the gut (#, c, f, i). Worms shown here were classified as old
(> a-c), middle aged (d, e, f), young (+, >, g, h, i).
doi:10.1371/journal.pntd.0005156.g002
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between the worms in one patient. Odds ratios (with 95% confidence intervals (CIs)) were
derived from the regression models to depict the difference between treatment groups with
respect to the outcome measurements (Wolbachia depletion, inhibition of embryogenesis,
occurrence of dead worms, FtsZ, actin, FTsZ/actin). Except for the variable "treatment groups",
no covariates were included as effects in the primary analyses. Quantitative PCR data were
log10-transformed before testing. Comparisons between histological outcome and PCR were
done using the unpaired t-test for dead vs. live and ANOVA followed by unpaired t-test for
no, many, few Wolbachia as well as ANOVA followed by Tukey’s method as post-hoc test for
comparison of embryogenesis.
For the analysis of Mf, the Wilcoxon-signed-rank-test was used for comparisons within the
patients before and after therapy and the Kruskal-Wallis-test for comparisons between all
groups. Baseline data were analyzed using ANOVA for patient age and weight, Fisher’s exact
test for gender and the Kruskal-Wallis test for number of nodules and sites.
Results
Participant flow and recruitment
The trial profile of the study is illustrated in Fig 1. Altogether, 158 volunteers from 14 villages
affected by onchocerciasis that met the inclusion criteria were enrolled into the study and sub-
sequently randomized into the following treatment arms: doxycycline 4 weeks (DOX 4w),
doxycycline 3 weeks (DOX 3w), doxycycline 3 weeks plus albendazole 3 days (DOX 3w + ALB
3d), minocycline 3 weeks (MIN 3w) or albendazole 3 days (ALB 3d) as equivalent to a negative
control (see Materials and Methods). Baseline data for the participants who took the drugs for
at least one day (ITT) with regard to gender, age, weight, and rounds of IVM of the volunteers
in each treatment group are given in Table 1. On average, participants had two palpable nod-
ules and one round of IVM prior to treatment begin. 39% of the study participants had never
taken IVM. Mf positivity and the intensity of microfilaridermia (Mf/mg skin) did not differ
between the groups at study onset with 63.6% Mf-positive individuals.
Since already 8 participants dropped out before (N = 2) or during the first 2 treatment days
(N = 6), 8 additional participants were randomized to avoid a higher drop-out rate than primarily
calculated. From 156 participants who had started treatment, 116 (73.4%) presented for nodulect-
omy (109 at the 6 months follow-up and 7 two months later); of these, 99 participants could be
included in the PP set (Fig 1), as they had completed treatment according to protocol, i.e. had not
been absent for more than 3 consecutive days or during the ALB period (treatment days 9–11).
Development of adverse reactions
During treatment, adverse reactions (AR) to the study drugs were monitored. The analyses
showed that although significant differences occurred between the study groups (S1 and S2
Tables), the adverse reactions reported were minor (Grade 1 or Grade 2, only once Grade 3)
and included stomach pain, dizziness, vomiting and nausea. Most of the reported AR occurred
in the combination group DOX 3w + ALB 3d, however AR were not associated with the time
point of ALB intake. The number and type of AR were similar in the DOX 4w and DOX 3w
group, therefore a longer treatment time does not alter AR. It is important to note that the
range of AR after DOX is similar to that seen in a previous study [10], in which DOX was used
in lower doses and was performed under blinded conditions. MIN associated AR were mainly
dizziness, a common side effect of this drug.
Taken together, the study drugs were well tolerated and no severe or unexpected events
occurred due to intake of the medications.
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Immunohistology
Depletion of Wolbachia. As primary outcome, the presence of Wolbachia endobacteria
in worm tissues was examined by immunohistology. All histological analyses were performed
PP as well as ITT (supplementary data).
In total, 272 nodules from 98 individuals (PP, Tables 2–4) and 307 nodules from 110 study
participants (ITT, S3–S5 Tables) were examined. 8.7% of all nodules (PP; ITT: 10.8%) could
not be analysed for viability status; the reasons for this included being of non-onchocercal ori-
gin (e.g. foreign body granulomas, lipomas or lymph nodes).
65% of the female worms in the control group (ALB 3d) were Wolbachia-positive (Table 2),
a level that is consistent with other endemic areas with lowered transmission and a higher pro-
portion of older worms [10], possibly induced by MDA or as a result of intensified gold dig-
ging and thus pollution of the water breeding habitat of the vector [38]. In contrast, only 1.3%
contained intact Wolbachia in the standard treatment group (DOX 4w). A similar difference
Table 1. Patient baseline data
Treatment
Total DOX 4w DOX 3w+ ALB 3d MIN 3w DOX 3w ALB 3d
Age (years) N 156 33 32 30 31 30
Mean ± SD 40.1 ± 10.0 40.6 ± 9.9 40.4 ± 10.3 41.0 ± 10.2 37.2 ± 9.4 41.6 ± 10.4
p = 0.4521a
Weight (kg) N 156 33 32 30 31 30
Mean ± SD 58.3 ± 7.7 59.0 ± 7.1 57.7 ± 8.5 58.7 ± 8.7 57.4 ± 6.6 58.9 ±7.5
p = 0.8812a
Sex female 63 (40.4%) 9 (27.3%) 14 (43.8%) 11 (36.7%) 14 (45.2%) 15 (50.0%)
male 93 (59.6%) 24 (72.7%) 18 (56.3%) 19 (63.3%) 17 (54.8%) 15 (50.0%)
p = 0.3859b
IVM Rounds N 156 33 32 30 31 30
Mean ± SD 1.0 ± 1.0 0.8 ± 0.9 1.0 ± 1.1 1.1 ± 1.0 1.2 ± 1.1 0.9 ±1.0
Min—Max 0–5.0 0–3.0 0–5.0 0–3.0 0–3.0 0–3.0
Median 1.0 1.0 1.0 1.0 1.0 1.0
Percentiles 25th;75th 1.0–2.0 0–1.0 0–2.0 0–2.0 0–2.0 0–1.0
p = 0.4222c
0 60 (38.5%) 15 (45.5%) 13 (40.6%) 10 (33.3%) 9 (29.0%) 13 (43.3%)
1 52 (33.3%) 11 (33.3%) 10 (31.3%) 9 (30.0%) 11 (35.5%) 11 (36.7%)
2 29 (18.6%) 5 (15.2%) 7 (21.9%) 8 (26.7%) 6 (19.4%) 3 (10.0%)
3 14 (9.0%) 2 (6.1%) 1 (3.1%) 3 (10.0%) 5 (16.1%) 3 (10.0%)
5 1 (0.6%) 0 1 (3.1%) 0 0 0
No. of Nodules N 156 33 32 30 31 30
Mean ± SD 2.6 ± 1.7 2.6 ± 1.9 2.7 ± 2.0 2.6 ± 1.7 2.8 ± 1.5 2.4 ± 1.3
Median 2.0 2.0 2.0 2.0 3.0 2.0
p = 0.7858c
No. of Sites N 156 33 32 30 31 30
Mean ± SD 1.8 ± 0.9 1.7 ± 1.1 1.9 ± 1.2 1.6 ± 0.8 1.8 ± 0.8 1.7 ± 0.7
Median 2.0 1.0 2.0 1.0 2.0 2.0
p = 0.5999c
a ANOVA
b Fisher’s Exact Test
c Kruskal-Wallis Test
doi:10.1371/journal.pntd.0005156.t001
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could be observed for male worms, with 56.5% Wolbachia positive worms in the ALB 3d
group and 12% in the standard DOX 4w group, respectively (Table 3).
All experimental treatment groups (DOX 3w+ALB 3d (OR 8.16 [3.1; 21.6], p< 0.0001),
MIN 3w (OR 5.8 [2.0; 17.0], p = 0.0016) and DOX 3w (OR 4.2 [1.4; 12.2], p = 0.0084) showed
superiority to the ALB 3d group when using alternating logistic regression. However, the
extent of Wolbachia depletion was superior in the DOX 4w group (OR 145 [18.8; 118.1], p<
0.0001), compared to all experimental treatment groups as well as to ALB 3d (OR 145 [18.8;
118.1], p< 0.0001; Table 4). Despite this finding, the DOX 3w+ALB 3d (81.4%) and the MIN
3w (72.7%) arms showed higher Wolbachia depletion compared to DOX 3w (64.1%) indicat-
ing a stronger efficacy. Furthermore, the ORs presented in Table 4 suggest that there is a possi-
ble synergistic effect of DOX 3w+ALB 3d compared to DOX 3w alone (OR 1,85 [0.63; 5.44]),
albeit not to a statistically significant degree (p = 0.2607). Under ITT conditions both groups
(DOX 3w+ALB 3d and MIN 3w) were not statistically different to DOX 4w (S3–S5 Tables).
This however does not imply their equivalence to the DOX 4w group, as the ORs 3.7 [0.6; 22]
and 5.1 [0.8; 32] still indicate a higher risk for presence of Wolbachia in both groups. In male
worms, Wolbachia were reduced significantly in the DOX 4w group compared to the ALB 3d
control group (OR 7.9 [1.7; 37.3], p = 0.0093) and to DOX 3w (OR 10.1 [2.2; 46.3], p = 0.0031).
To exclude the possibility that prior MDA participation may have influenced Wolbachia
depletion, the alternating logistic regression was additionally performed with prior IVM-
rounds as single effect variable showing no effect on the outcome (p = 0.7932). Including prior
IVM rounds as covariate in the treatment model revealed no relevant influence on the treat-
ment effects described above.
All these findings indicate a trend towards a better efficacy of DOX 3w + ALB 3d or MIN
3w compared to DOX 3w but designed as a non-confirmatory pilot trial the study was not
Table 2. Effect of the study drugs on presence of Wolbachia in female worms: histology
Treatment Group No. of Patients/ Nod a No. of living female worms
All Wolbachia levels
98 / 272 334 many few none
DOX 4w (Standard) 24 / 62 80 0 1 (1.3%) 79 (98.8%)
DOX 3w + ALB 3d 18 / 54 70 0 13 (18.6%) 57 (81.4%)
MIN 3w 19 / 46 66 0 18 (27.3%) 48 (72.7%)
DOX 3w 18 / 46 64 1 (1.6%) 22 (34.4%) 41 (64.1%)
ALB 3d 19 / 64 54 5 (9.3%) 30 (55.6%) 19 (35.2%)
a Only evaluable patients/nodules are included.
doi:10.1371/journal.pntd.0005156.t002
Table 3. Effect of the study drugs on presence of Wolbachia in male worms: histology
Treatment Group No. of Patients/ Nod a No. of living male worms
Allb Wolbachia levels
98 / 272 119 many few none
DOX 4w (Standard) 24 / 62 25 0 3 (12.0%) 22 (88.0%)
DOX 3w + ALB 3d 18 / 54 23 3 (13.0%) 4 (17.4%) 16 (69.6%)
MIN 3w 19 / 46 23 4 (17.4%) 4 (17.4%) 15 (65.2%)
DOX 3w 18 / 46 25 3 (12.0%) 12 (48.0%) 10 (40.0%)
ALB 3d 19 / 64 23 2 (8.7%) 11 (47.8%) 10 (43.5%)
a Only evaluable patients/nodules are included.
doi:10.1371/journal.pntd.0005156.t003
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planned to detect such subtle differences. A larger confirmatory trial setting would be needed
to identify whether DOX 3w + ALB 3d or MIN 3w are better than DOX 3w.
In summary, the data shown here provide evidence that all treatments are superior to ALB
in their ability to deplete Wolbachia with DOX 4w showing the strongest efficacy.
Inhibition of embryogenesis. As a secondary endpoint of the study, we investigated the
drug-induced blockade of worm embryogenesis, being defined as the proportions of worms
with normal or degenerated embryogenesis. For this analysis, we considered the different
activities of DOX, ALB and IVM on embryogenesis. IVM has been demonstrated to lead to
degeneration of stretched Mf in the uterus whilst there is limited to no effect on the morulae
and coiled Mf stages [14]. In contrast, anti-wolbachial therapy inhibits the early stages of
embryogenesis. Although DOX does not affect fully developed Mf, neither in utero nor after
release when free in the host’s tissues, there is evidence that they may be inhibited from devel-
oping within the vector [39]. ALB has only minor effects on embryonic stages of O. volvulus
[31, 40, 41]. We found that in the ALB 3d group 17.7% of all 54 female worms analyzed had
normally developed embryos (Table 5; S6 and S7 Tables) and 12.8% of the nodules were Mf-
positive (Table 7, S8 Table). In contrast, in the DOX 4w group only 8% of all 75 female worms
contained normal embryos and all nodules were Mf-negative. Similarly, only 14.7% of 68
Table 4. Effect of the study drugs on presence of Wolbachia in female worms: statisticsa, b
PP, female DOX 3w + ALB 3d MIN 3w DOX 3w ALB 3d
DOX 4w p = 0.0052OR 17.98 [2.37;
136.1]
p = 0.0022OR 25.97 [3.24;
208.33]
p = 0.0007OR 36.24 [4.55;
288.84]
p<0.0001OR 145.0 [18.8;
118.08
DOX 3w + ALB
3d
p = 0.5538OR 1.36 [0.47; 4.08] p = 0.2607OR 1.85 [0.63; 5.44] p<0.0001OR 8.16 [3.08;
21.57]
MIN 3w p = 0.5981OR 1.36 [0.43; 4.28] p = 0.0016OR 5.76 [1.95;
17.03]
DOX 3w p = 0.0084OR 4.2 [1.44; 12.2]
a Alternating logistic regression (comparison of presence (many and few) vs. absence of Wolbachia)
b Table shows the odds ratios (OR) for presence of Wolbachia comparing the treatment groups in the headline to the treatment groups in the left column.
doi:10.1371/journal.pntd.0005156.t004
Table 5. Effect of the study drugs on embryogenesis: histology
Treatment Group No. of Patients/Nod a No.of living female worms
All Embryos Sperms in Uterus
98 / 272 334 not judgeable oocytes only / uterus empty normal degenerated
DOX 4w (Standard) 24 / 62 80 5 57 (76.0%) 6 (8.0%) 12 (16.0%) 10 (12.5%)
(33.3%)b (66.7%)b
DOX 3w + ALB 3d 18 / 54 70 2 42 (61.8%) 10 (14.7%) 16 (23.5%) 14 (20.0%)
(38.5%)b (61.5%)b
MIN 3w 19 / 46 66 6 41 (68.3%) 7 (11.7%) 12 (20.0%) 7 (10.6%)
(36.8%)b (63.2%)b
DOX 3w 18 / 46 64 2 42 (67.7%) 11 (17.7%) 9 (14.5%) 10 (15.6%)
(55.0%)b (45.0%)b
ALB 3d 19 / 64 54 3 39 (76.7%) 9 (17.7%) 3 (5.9%) 9 (16.7%)
(75.0%)b (25.0%)b
a Only evaluable patients/nodules are included.
b % of all female worms with embryogenesis within the respective group
doi:10.1371/journal.pntd.0005156.t005
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female worms analyzed in the DOX 3w+ALB 3d group showed normal embryogenesis with
8.7% Mf-positive nodules. Comparison of DOX 4w and DOX 3w plus Alb 3d to Alb 3d alone
using alternating logistic regression showed a higher risk for the Alb 3d group to maintain liv-
ing female worms with normal embryogenesis compared to worms with degenerated embryo-
genesis (OR 4 [1.2; 13.8], p = 0.0283; OR 4.8 [1.1; 21.5], p = 0.0423, respectively, Table 6). A
trend for reduction of normal embryogenesis within female worms was also seen in the MIN
3w group (11.7%) and, to a lesser extent, in the DOX 3w group with 17.7% females showing
normal embryogenesis in 62 female worms analyzed.
To examine a possible influence of the prior IVM round on the embryogenesis, the alternat-
ing logistic regression was additionally performed with prior IVM-rounds as single effect vari-
able showing a tendency towards normal embryogenesis versus degenerated embryogenesis in
patients with fewer IVM-rounds (OR 1.5 [0.96; 2.24], p = 0.0745). But, including prior IVM-
rounds as covariate in the treatment model revealed again no relevant influence on the treat-
ment effects described above.
In summary, the data show that a combination of DOX 3w with ALB 3d leads to small but
detectable additive effects in depleting Wolbachia and thereby probably increased inhibition of
embryogenesis in both data sets (Tables 5–7 and S6–S8 Tables). Furthermore, the partial effect
of MIN 3w compared to DOX 3w suggests that when used for longer treatment times, minocy-
cline is more efficacious than doxycycline.
Effect on adult worms. The aim of this study was the investigation of Wolbachia absence
at 6 months post treatment to identify drug regimens with faster–acting antibiotic activity.
Wolbachia reduction has been shown to precede macrofilaricidal activity and earlier studies by
our group have shown that an observation period of 20 and 27 months is needed in order to
observe macrofilaricidal effects [15]. Still, we analyzed the number of dead worms in the differ-
ent treatment groups. 41.8% dead females and 4.0% dead males were found at 6 months post
Table 6. Effect of the study drugs on embryogenesis: statisticsa
PP DOX 3w + ALB 3d MIN 3w DOX 3w ALB 3d
DOX 4w p = 0.7862OR 1.16 [0.41;3.3] p = 0.7245OR 1.28 [0.32;5.13] p = 0.0571OR 1.98 [0.98;4.0] p = 0.0283OR 4.0 [1.16;13.83]
DOX 3w + ALB 3d p = 0.937 OR 0.94 [0.23;3.87] p = 0.2417OR 1.96 [0.64;6.06] p = 0.0423OR 4.77 [1.06;21.54]
MIN 3w p = 0.3613OR 2.0 [0.45;8.89] p = 0.1182 OR 4.07 [0.7;23.7]
DOX 3w p = 0.2149 OR 2.51 [0.59;10.77]
a alternating logistic regression, comparison of normal vs. degenerated embryogenesis
b Table shows the odds ratios (OR) for embryogenesis comparing the treatment groups in the headline to the treatment groups in the left column.
doi:10.1371/journal.pntd.0005156.t006
Table 7. Effect of the study drugs on Mf within the nodule: histology
Treatment Group No. of Patients/Noda No. of Nodulesb
All with intact mf
98 / 272 208
DOX 4w 24 / 62 53 0
DOX 3w + ALB 3d 18 / 54 46 4 (8.7%)
MIN 3w 19 / 46 38 2 (5.3%)
DOX 3w 18 / 46 32 2 (6.3%)
ALB 3d 19 / 64 39 5 (12.8%)
a Only evaluable patients/nods are included
b Only nodules with living female worms are included
doi:10.1371/journal.pntd.0005156.t007
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treatment. There were no significant differences between the study groups. On average, each
nodule contained a total of 2.11 females (1.23 living females, 0.88 dead females) and 0.46 males
(0.44 living males, 0.02 dead males).
Real-time PCR
Depletion of Wolbachia. Real-time polymerase chain reaction is a very sensitive tech-
nique that allows the quantification of a given DNA segment. We wanted to investigate
whether PCR detection of Wolbachia DNA confirms the results as read by immunohistology
and thereby offers an option for quantification of Wolbachia levels directly from histological
sections, leaving the nodule otherwise intact for further histological investigations. Therefore,
DNA from 8 sections adjacent to the ones analyzed with histology were chosen and analyzed
for Wolbachia FtsZ and nematode actin. We were able to isolate DNA from all but 5 nodules
that were analyzed with immunohistology (see above).
Importantly, the FtsZ as well as the FtsZ/actin ratio (Table 8) confirm the immunohistology
results and similar gradations occurred between the groups and the control group, with DOX
4w weeks showing the strongest reduction, followed by DOX 3w + ALB 3d, MIN 3w and DOX
3w in the PP data set (Tables 9–11) as well as the ITT dataset (S9–S12 Tables). Actin levels did
not differ between the groups, since nodules with dead or resorbed worms only were sub-
tracted prior to this statistical analysis.
The lack of complete absence of Wolbachia for example in the DOX 4w group, may result
from an inability of the worm to degrade the Wolbachia DNA within 6 months, whereas their
bacterial function and histological visibility is already lost.
Comparison of immunohistology and real-time PCR. Both, FtsZ and actin may be
strongly influenced by the numbers of worm sections within a sample, the presence of oocytes
or further developed stages within the female worms or whether the worms found in the nod-
ule sections are alive or dead. Therefore we subdivided the Wolbachia depletion data according
Table 8. Effect of the study drugs on presence of Wolbachia in nodule sections: PCRa,b
DOX 4w DOX 3w + ALB 3d MIN 3w DOX 3w ALB 3d
FtsZ N 53 47 39 36 41
Median 410 960 3870 2990 8460
95% CI (Median) 128;933 485;3260 580;5790 1000;6425 5210;13500
Percentiles 25th;75th 75;2310 163;6030 278;8430 369;13550 2840;28100
Min—Max 0.06–25600 0.21–195000 0.03–99000 0.00–131000 0.27–130000
Actin N 53 47 39 36 41
Median 1170 2020 981 1365 1230
95% CI (Median) 933;2239 901;3810 448;2430 413;3030 650;1875
Percentiles 25th;75th 470;3190 638;6340 354;5480 204;5743 262;3190
Min—Max 4.30–27900 11.70–48600 9.18–405000 1.94–114000 37.30–45300
FtsZ/Actin N 53 47 39 36 41
Median 0.25 0.51 1.23 1.36 11.14
95% CI (Median) 0.09;0.79 0.42;0.82 0.4;2.72 1.06;4.03 2.09;23.13
Percentiles 25th;75th 0.03;1.60 0.22;2.63 0.20;6.24 0.66;5.35 1.40;36.75
Min—Max 0–27.44 0–45.03 0–250.54 0–79.03 0–2832.24
a Normally one PCR per nodule (from 3 nodules 2 PCRs were done and the mean was taken for further analyses (DOX 4w N = 2, DOX 3w N = 1), in 1
nodule PCR could not be performed (DOX 4w))
b For the analyses, PCRs from all nodule with dead worms only were excluded from this table and from all following analyses
doi:10.1371/journal.pntd.0005156.t008
Comparison of DOX, MIN, DOX plus ALB and ALB Alone in Their Efficacy against Onchocerciasis
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005156 January 5, 2017 13 / 22
to the histological differentiation of i) dead worms vs. live worms and to ii) live worms with
no, few or many Wolbachia (Fig 3A). Accordingly, the Wolbachia signal FtsZ and the filarial
actin were low in nodules containing dead worms only compared to nodules containing also
live worms (p< 0.001 ANOVA). FtsZ, actin as well as the FtsZ/actin ratio reflected the
increase of Wolbachia showing significant differences between no and few or no and many
Wolbachia. Furthermore, a difference between few and many Wolbachia could be detected by
the Wolbachia signal FtsZ (p = 0.015).
In addition, grouping by embryogenesis showed a relation of the FtsZ to the normal devel-
opment of oocytes and embryos in the female worm. The actin level revealed a strong depen-
dency from the presence of oocytes or embryos within the uterus of the females, reflecting the
increased amount of nuclei with offspring production (Fig 3B).
Thus, the PCR performed on nodule tissue section reflected the histological evaluation.
Effect on microfilaridermia. Of the 102 study participants who completed the treatment
per protocol and were present for skin snipping after 6 months, 65 (63.7%) were microfilari-
dermic (Mf-positive) at entry to the study, with the remaining 37 (36.3%) having no detectable
skin microfilariae but only palpable nodules before treatment. In accordance to our earlier
study [35], at the 6-month follow-up time point, no significant differences in the number of
Mf-carriers were observed between the groups themselves and compared to pretreatment,
indicating that this time point is too early to observe study treatment-induced reduction of
peripheral Mf (Table 12; S13 Table). Similarly, there was no significant difference in the Mf
Table 9. Effect of the study drugs on presence of Wolbachia in nodule sections: statistics for FtsZa,b
PP DOX 3w + ALB 3d MIN 3w DOX 3w ALB 3d
DOX 4w p = 0.0954 p = 0.0403 p = 0.061 p<0.0001
OR 3.05 [0.82;11.35] OR 4.51 [1.07;19.05] OR 4.3 [0.94;19.73] OR 22.46 [6.99;72.15]
DOX 3w + ALB 3d p = 0.5455 p = 0.6702 p = 0.0006
OR 1.54 [0.38;6.21] OR 1.38 [0.32;6.02] OR 6.88 [2.3;20.59]
MIN 3w p = 0.9193 p = 0.0168
OR 0.92 [0.19;4.55] OR 4.68 [1.32;16.59]
DOX 3w p = 0.0171
OR 5.11 [1.34;19.52]
a Alternating linear regression (after log10-transformation (all values +0.1 to circumvent zero values))
b Table shows the odds ratios (OR) for presence of Wolbachia comparing the treatment groups in the headline to the treatment groups in the left column.
doi:10.1371/journal.pntd.0005156.t009
Table 10. Effect of the study drugs on presence of Wolbachia in nodule sections: statistics for Actina
PP DOX 3w + ALB 3d MIN 3w DOX 3w ALB 3d
DOX 4w p = 0.3888 p = 0.6398 p = 0.6897 p = 0.8569
OR 1.43 [0.64;3.2] OR 1.25 [0.49;3.2] OR 0.79 [0.25;2.53] OR 0.93 [0.4;2.15]
DOX 3w + ALB 3d p = 0.8214 p = 0.3758 p = 0.3281
OR 0.89 [0.34;2.35] OR 0.58 [0.18;1.92] OR 0.65 [0.27;1.55]
MIN 3w p = 0.5971 p = 0.6193
OR 0.71 [0.2;2.5] OR 0.78 [0.29;2.1]
DOX 3w p = 0.734
OR 1.23 [0.37;4.12]
a Alternating linear regression (after log10-transformation (all values +0.1 to circumvent zero values)) b Table shows the odds ratios (OR) for presence of
Wolbachia comparing the treatment groups in the headline to the treatment groups in the left column.
doi:10.1371/journal.pntd.0005156.t010
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load (median Mf/mg skin) between all treatment groups prior to treatment (Table 13; S14
Table). And, also after 6 months, no differences between the groups occurred. However, a sta-
tistically significant decrease in the ALB 3d group (p = 0.047, median pre-treatment 0.4,
median 6 months 0.2) and a trend in the DOX 4w group (p = 0.091, median pre-treatment 2.3,
median 6 months 0.7) was observed. Both results could be confirmed by the ITT analysis (ALB
3d: p = 0.025, DOX 4w: p = 0.028).
Discussion
Immense efforts have been undertaken in many countries to achieve elimination of onchocer-
ciasis by MDA. However, still 130 million people are at risk of infection [1]. Current
approaches to increase the frequency of MDA from annual to biannual treatments are pre-
dicted to improve the chances of reaching the 2020/2025 elimination goals at least in some
countries. However, its benefits and costs are highly sensitive to systematic noncompliance
and it may not always be feasible to implement biannual treatment, particularly in hard-to-
reach populations [6, 7, 42]. In addition, given the problem of re-emergence of infections, sub-
optimal efficacy of IVM [10] and regions that are co-endemic for Loa loa, the development of
new drugs or drug regimens is urgently needed to achieve the elimination of onchocerciasis.
This would increase cost effectiveness by avoiding unnecessary treatments of uninfected indi-
viduals within the MDA schemes, especially in “end-game” scenarios or when switching from
MDA to “test & treat” strategies.
In this study, we have compared DOX 4w, MIN 3w, DOX 3w plus ALB 3d, DOX 3w and
ALB 3d alone in their efficacy against onchocerciasis in a randomized, open-label pilot trial.
Since we have shown earlier that Wolbachia depletion precedes the inhibition of embryogene-
sis and adult worm death [14, 15, 43], the follow-up at 6 months post treatment was chosen to
investigate the primary outcome, i.e. Wolbachia reduction. In the present study, histological
analyses of the adult worms within the extirpated nodules 6 months after treatment revealed a
Wolbachia reduction of 99% in the DOX 4w group showing superiority to all other treatment
arms. Accordingly, the extent of Wolbachia depletion was highest in the DOX 4w group, fol-
lowed by DOX 3w + ALB 3d, MIN 3w and then DOX 3w compared to ALB 3d. The Wolbachia
reduction in the DOX 4w group was comparable to that of a 6-week 200 mg/d regimen with
DOX after 6 months [15]. In addition, real-time PCR analysis from DNA isolated from paraf-
fin embedded histological sections revealed that similar gradations occurred between the
groups, suggesting the use of real-time PCR as a sensitive method for the quantification of
Wolbachia loads within the worms after a given treatment. We further validated the FtsZ and
Table 11. Effect of the study drugs on presence of Wolbachia in nodule sections: statistics for FtsZ/Actina,b
PP DOX 3w + ALB 3d MIN 3w DOX 3w ALB 3d
DOX 4w p = 0.3403 p = 0.0168 p = 0.0036 p<0.0001
OR 1.43 [0.69;2.97] OR 2.63 [1.19;5.81] OR 3.07 [1.44;6.54] OR 11.69 [4.88;28.02]
DOX 3w + ALB 3d p = 0.2097 p = 0.0634 p<0.0001
OR 1.68 [0.75;3.78] OR 2.05 [0.96;4.39] OR 7.66 [3.18;18.47]
MIN 3w p = 0.6526 p = 0.0004
OR 1.19 [0.55;2.57] OR 4.88 [2.02;11.81]
DOX 3w p = 0.0017
OR 4.04 [1.69;9.69]
a Alternating linear regression (after log10-transformation (all values +0.1 to circumvent zero values))
b Table shows the odds ratios (OR) for presence of Wolbachia comparing the treatment groups in the headline to the treatment groups in the left column.
doi:10.1371/journal.pntd.0005156.t011
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Fig 3. Comparison of immunohistology and real-time PCR (Wolbachia depletion and embryogenesis). FtsZ, actin copy numbers and the
FtsZ/actin ratio are shown. (A) Data were split by their immunohistological outcome (Wolbachia content, live vs. dead worms) and significances were
calculated for 1) nodules containing dead worms only vs. all nodules containing live worms and 2) nodules containing live worms separated into no,
few or many Wolbachia. (B) Data were split by their immunohistological outcome (embryogenesis). The overall comparisons regarding embryogenesis
showed a significant correlation for FtsZ, actin and FtsZ/actin copies (p< 0.001, respectively; ANOVA). Tukey’s method was used for post-hoc
comparisons.
doi:10.1371/journal.pntd.0005156.g003
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actin signal by subdividing the data according to the biological status of the worm (live, dead,
Wolbachia levels and empty uterus and embryogenesis). FtsZ levels increased according to the
histologically defined Wolbachia categories, whereas actin levels were elevated, when worms
were alive compared to dead worms. In addition, actin levels were associated with increased
embryogenesis.
Inhibition of embryogenesis after doxycycline/anti-wolbachial therapy leading to sterile
females has been shown to result in the absence of Mf in the skin of infected patients, a
requirement for interruption of transmission Therefore, embryogenesis was analyzed as sec-
ondary outcome histologically within the nodules as well as by skin MF loads. We found that
already after 6 months only 8% (DOX 4w), 14.7% (DOX 3w + ALB 3d), 11.7% (MIN 3w),
17.7% (DOX 3w) of the living female worms with embryogenesis had normal embryonal
development compared to 17.7% (ALB 3d). DOX 4w and DOX 3w + ALB 3d showed a higher
number of female worms with degenerated embryogenesis compared to ALB 3d and reached
statistical significance (OR 4, p = 0.0283; OR 4.8, p = 0.0423, respectively), whereas MIN 3w
Table 12. Microfilaridermia
Pre-treatment 6 months
Mf-positive Mf-negative Mf-positive Mf-negative
DOX 4w 16 (66.7%) 8 (33.3%) 16 (66.7%) 8 (33.3%)
DOX 3w + ALB 3d 11 (61.1%) 7 (38.9%) 13 (72.2%) 5 (27.8%)
MIN 3w 13 (61.9%) 8 (38.1%) 12 (57.1%) 9 (42.9%)
DOX 3w 12 (63.2%) 7 (36.8%) 11 (57.9%) 8 (42.1%)
ALB 3d 13 (65.0%) 7 (35.0%) 12 (60.0%) 8 (40.0%)
doi:10.1371/journal.pntd.0005156.t012
Table 13. Levels of Mf
Treatment
DOX 4w DOX 3w DOX 3w + ALB 3d MIN 3w ALB 3d
Pre-treatmentc N 24 19 18 21 20
Mean ± SD 5.3 ± 7.5 6.2 ± 11.2 6.1 ± 10.5 4.7 ± 13.4 4.5 ± 9.7
GMa 2.4 1.8 2.3 1.2 1.4
Min—Max 0–28.0 0–36.3 0–40.2 0–61.0 0–38.9
Median 2.3 0.4 2.1 0.3 0.4
95% CI (median) 0;4.7 0;0.2 0;4.7 0;2.1 0;3.3
Percentiles 25th;75th 0; 6.0 0; 7.4 0; 4.8 0; 2.1 0; 4.5
6 monthsd N 24 19 18 21 20
Mean ± SD 3.8 ± 7.4 10.1 ± 36.0 4.4 ± 7.8 6.1 ± 14.2 3.0 ± 6.9
GMa 1.5 1.3 1.5 1.4 1.0
Min—Max 0–33.4 0–157.8 0–21.1 0–48.0 0–29.0
Median 0.7 0.4 0.7 0.3 0.2
95% CI (median) 0;2.9 0;1.2 0;1.4 0;3.0 0;1.4
Percentiles 25th;75th 0; 4.5 0; 1.3 0; 1.9 0; 4.0 0; 2.2
p-valueb p = 0.091 p = 0.397 p = 0.196 p = 0.877 p = 0.047
SD = standard deviation, GM = geometric mean
a The geometric mean (GM) was calculated by adding 1 to all values and after the calculation 1 was again subtracted from the result
b Wilcoxon-signed-rank-test
c No difference between all 5 treatment groups pre-treatment (p = 0.799, Kruskal-Wallis-test)
d No difference between all 5 treatment groups at 6 months (p = 0.859, Kruskal-Wallis-test)
doi:10.1371/journal.pntd.0005156.t013
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and DOX 3w did not. An overall low number of nodules contained MF. However, similar to
the results on the absence of Wolbachia, the extent of inhibition of normal embryogenesis fol-
lows the same order with the highest being in the DOX 4w group, followed by DOX 3w + ALB
3d, MIN 3w and finally DOX 3w. All findings could be confirmed within the ITT analysis.
Other secondary outcomes were microfilaridermia as well as the number of dead worms
within the nodules. The 6-months time point is too early for the treatment efficacy to be
reflected in the disappearance of peripheral Mf in the skin, since Mf are not killed directly by
anti-wolbachial drugs (an advantage e.g. in Loa co-endemic areas). In an earlier study, despite
the percentage of females with degenerated embryogenesis being increased to 95.5% at 6
months after 6 weeks doxycycline treatment [15], all individuals were still Mf-positive. Simi-
larly, Mf counts were not significantly different between the groups in the present study and
62.7% of the patients were Mf-positive at 6 months after treatment.
Also for the observation of macrofilaricidal efficacy a comparatively long observation
period is needed and we have shown that a distinct macrofilaricidal effect can be seen with
female worms at 20 and 27 months following a six week treatment course with 200 mg DOX
per day [15]. Therefore, similar to the absence of effects on microfilaridermia after 6 months,
expectedly no differences could be found in the number of dead worms histologically analyzed
within the nodules. Despite this, our data provide clear evidence that the time point of 6
months after treatment can be used for the analysis of Wolbachia depletion and in utero inhi-
bition of embryogenesis and is appropriate for identification of anti-wolbachial drugs or drug
regimens.
In our study, the 6 months analysis shows that reducing the treatment time with DOX from
4 to 3 weeks is not recommended, as DOX 4w is clearly superior to DOX 3w in Wolbachia
depletion and inhibition of normal embryogenesis. Therefore a four weeks course of 200 mg
DOX should be further recommended to achieve long-term female worm sterility and death
[44, 45].
In addition, the combination of 3 weeks of DOX and ALB 3d showed a higher extent of
Wolbachia depletion compared to 3 weeks of DOX alone, indicating an additive effect when
used in combination. Studies to determine whether drug-drug interactions or other mecha-
nisms of action of combinations of anti-Wolbachia drugs and anti-filarial drugs lead to
enhanced anti-Wolbachia and macrofilaricidal effects to further shorten treatment regimens
are currently underway as part of the AWOL programme.
Minocycline, MIN, another broad-spectrum tetracycline antibiotic, was revealed in an in
vitro assay exposing O. gutturosa adult males to be more active than DOX [29], as measured by
motility of adult worms and viability by reduction of MTT to MTT formazan assay. Since
MIN was also among the top hits of the AWOL screening activities [3], these data were
recently confirmed using the Wolbachia containing insect cell line C6/36. On top of that, data
generated from a rodent infection model using Litomosoides sigmodontis confirmed the effi-
cacy in vivo, showing a similar superiority of MIN over DOX (Specht et al, in preparation,
[30]). Our clinical data reported here support that MIN may actually be more efficacious than
DOX, since MIN showed a trend for being better than DOX 3w in the relevant comparisons,
i.e. absence of Wolbachia, inhibition of normal embryogenesis. The differences did however
not reach statistical significance, as the pilot trial design was not sufficiently powered to detect
these differences.
In summary, these results provide further evidence and confirm earlier studies [15] that
DOX 4w is sufficient for Wolbachia depletion and the desired parasitological effects, i.e. deple-
tion of Wolbachia, inhibition of embryogenesis, whereas DOX 3w delivers sub-optimal effects.
The data presented here further suggest that there is an additive effect of ALB 3d on top of that
of DOX 3w alone, since for both outcomes (Wolbachia depletion, inhibition of embryogenesis),
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this group showed the second strongest efficacy after DOX 4w. Furthermore, MIN 3w albeit not
significant showed a trend for being more efficacious compared to DOX 3w. This may suggest
that when used for longer treatment times, MIN may actually be more efficacious than DOX.
These latter two results are preliminary and need confirmation in a full-randomized controlled
phase 2 trial.
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